A Phase Ia/Ib Study of the Safety and Immunogenicity of a Xenogeneic Tyrosinase DNA Vaccine Melanoma View Homepage


Ontology type: schema:MedicalStudy     


Clinical Trial Info

YEARS

2007-2010

ABSTRACT

The purpose of this study is to evaluate the safety and immunogenicity of a DNA vaccine encoding a melanosomal antigen in melanoma patients at risk for disease progression or recurrence. In this study, the vaccine will be administered intramuscularly using a device that applies brief electrical fields to the tissue at the site of injection (a technique known as electroporation). It is expected that this device will improve the delivery of the vaccine. This study is being performed to determine if this procedure can be administered safely and if it is capable of inducing immune responses to the vaccine. Detailed Description This study is designed to evaluate administration of a xenogeneic DNA vaccine encoding the melanosomal antigen tyrosinase by in vivo electroporation in patients with malignant melanoma. The objectives of the study are to characterize the safety and immunogenicity of a DNA vaccine encoding the murine tyrosinase gene delivered administered intramuscularly using the electroporation based TriGrid Delivery System (Ichor Medical Systems). We will assess the nature, frequency, and severity of any toxicity associated with vaccination at escalating pINGmuTyr doses and then expand enrollment at then expand enrollment at the Maximum Tolerated Dose to assess immunologic responses to the tyrosinase antigen. The hypotheses being tested are that the procedure is feasible and safe and that it induces immune responses specific for tyrosinase in patients with stage IIB-IV malignant melanoma. More... »

URL

https://clinicaltrials.gov/show/NCT00471133

JSON-LD is the canonical representation for SciGraph data.

TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT

[
  {
    "@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json", 
    "about": [
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/3103", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "type": "DefinedTerm"
      }
    ], 
    "description": "The purpose of this study is to evaluate the safety and immunogenicity of a DNA vaccine encoding a melanosomal antigen in melanoma patients at risk for disease progression or recurrence. In this study, the vaccine will be administered intramuscularly using a device that applies brief electrical fields to the tissue at the site of injection (a technique known as electroporation). It is expected that this device will improve the delivery of the vaccine. This study is being performed to determine if this procedure can be administered safely and if it is capable of inducing immune responses to the vaccine.\n\nDetailed Description\nThis study is designed to evaluate administration of a xenogeneic DNA vaccine encoding the melanosomal antigen tyrosinase by in vivo electroporation in patients with malignant melanoma. The objectives of the study are to characterize the safety and immunogenicity of a DNA vaccine encoding the murine tyrosinase gene delivered administered intramuscularly using the electroporation based TriGrid Delivery System (Ichor Medical Systems). We will assess the nature, frequency, and severity of any toxicity associated with vaccination at escalating pINGmuTyr doses and then expand enrollment at then expand enrollment at the Maximum Tolerated Dose to assess immunologic responses to the tyrosinase antigen. The hypotheses being tested are that the procedure is feasible and safe and that it induces immune responses specific for tyrosinase in patients with stage IIB-IV malignant melanoma.", 
    "endDate": "2010-05-01T00:00:00Z", 
    "id": "sg:clinicaltrial.NCT00471133", 
    "keywords": [
      "safety", 
      "immunogenicity", 
      "DNA vaccine", 
      "antigen", 
      "melanoma patient", 
      "risk", 
      "disease progression", 
      "Recurrence", 
      "vaccine", 
      "Equipment and Supply", 
      "electrical field", 
      "tissue", 
      "injection", 
      "technique", 
      "electroporation", 
      "delivery", 
      "method", 
      "immune response", 
      "Organization and Administration", 
      "vivo electroporation", 
      "patient", 
      "melanoma", 
      "gene", 
      "delivery system", 
      "medical system", 
      "nature", 
      "frequency", 
      "severity", 
      "toxicity", 
      "vaccination", 
      "escalating", 
      "enrollment", 
      "maximum tolerated dose", 
      "immunologic response", 
      "hypothesise", 
      "Monophenol Monooxygenase"
    ], 
    "name": "A Phase Ia/Ib Study of the Safety and Immunogenicity of a Xenogeneic Tyrosinase DNA Vaccine Melanoma", 
    "sameAs": [
      "https://app.dimensions.ai/details/clinical_trial/NCT00471133"
    ], 
    "sdDataset": "clinical_trials", 
    "sdDatePublished": "2019-03-07T15:22", 
    "sdLicense": "https://scigraph.springernature.com/explorer/license/", 
    "sdPublisher": {
      "name": "Springer Nature - SN SciGraph project", 
      "type": "Organization"
    }, 
    "sdSource": "file:///pack/app/us_ct_data_00003.json", 
    "sponsor": [
      {
        "id": "https://www.grid.ac/institutes/grid.51462.34", 
        "type": "Organization"
      }, 
      {
        "id": "https://www.grid.ac/institutes/grid.282549.0", 
        "type": "Organization"
      }
    ], 
    "startDate": "2007-04-01T00:00:00Z", 
    "subjectOf": [
      {
        "id": "sg:pub.10.1186/2051-1426-1-20", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1035943441", 
          "https://doi.org/10.1186/2051-1426-1-20"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1186/2051-1426-1-20", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1035943441", 
          "https://doi.org/10.1186/2051-1426-1-20"
        ], 
        "type": "CreativeWork"
      }
    ], 
    "type": "MedicalStudy", 
    "url": "https://clinicaltrials.gov/show/NCT00471133"
  }
]
 

Download the RDF metadata as:  json-ld nt turtle xml License info

HOW TO GET THIS DATA PROGRAMMATICALLY:

JSON-LD is a popular format for linked data which is fully compatible with JSON.

curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/clinicaltrial.NCT00471133'

N-Triples is a line-based linked data format ideal for batch operations.

curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/clinicaltrial.NCT00471133'

Turtle is a human-readable linked data format.

curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/clinicaltrial.NCT00471133'

RDF/XML is a standard XML format for linked data.

curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/clinicaltrial.NCT00471133'


 

This table displays all metadata directly associated to this object as RDF triples.

61 TRIPLES      16 PREDICATES      53 URIs      45 LITERALS      1 BLANK NODES

Subject Predicate Object
1 sg:clinicaltrial.NCT00471133 schema:about anzsrc-for:3103
2 schema:description The purpose of this study is to evaluate the safety and immunogenicity of a DNA vaccine encoding a melanosomal antigen in melanoma patients at risk for disease progression or recurrence. In this study, the vaccine will be administered intramuscularly using a device that applies brief electrical fields to the tissue at the site of injection (a technique known as electroporation). It is expected that this device will improve the delivery of the vaccine. This study is being performed to determine if this procedure can be administered safely and if it is capable of inducing immune responses to the vaccine. Detailed Description This study is designed to evaluate administration of a xenogeneic DNA vaccine encoding the melanosomal antigen tyrosinase by in vivo electroporation in patients with malignant melanoma. The objectives of the study are to characterize the safety and immunogenicity of a DNA vaccine encoding the murine tyrosinase gene delivered administered intramuscularly using the electroporation based TriGrid Delivery System (Ichor Medical Systems). We will assess the nature, frequency, and severity of any toxicity associated with vaccination at escalating pINGmuTyr doses and then expand enrollment at then expand enrollment at the Maximum Tolerated Dose to assess immunologic responses to the tyrosinase antigen. The hypotheses being tested are that the procedure is feasible and safe and that it induces immune responses specific for tyrosinase in patients with stage IIB-IV malignant melanoma.
3 schema:endDate 2010-05-01T00:00:00Z
4 schema:keywords DNA vaccine
5 Equipment and Supply
6 Monophenol Monooxygenase
7 Organization and Administration
8 Recurrence
9 antigen
10 delivery
11 delivery system
12 disease progression
13 electrical field
14 electroporation
15 enrollment
16 escalating
17 frequency
18 gene
19 hypothesise
20 immune response
21 immunogenicity
22 immunologic response
23 injection
24 maximum tolerated dose
25 medical system
26 melanoma
27 melanoma patient
28 method
29 nature
30 patient
31 risk
32 safety
33 severity
34 technique
35 tissue
36 toxicity
37 vaccination
38 vaccine
39 vivo electroporation
40 schema:name A Phase Ia/Ib Study of the Safety and Immunogenicity of a Xenogeneic Tyrosinase DNA Vaccine Melanoma
41 schema:sameAs https://app.dimensions.ai/details/clinical_trial/NCT00471133
42 schema:sdDatePublished 2019-03-07T15:22
43 schema:sdLicense https://scigraph.springernature.com/explorer/license/
44 schema:sdPublisher N2857001668f64ca9937363f3ea64b5fd
45 schema:sponsor https://www.grid.ac/institutes/grid.282549.0
46 https://www.grid.ac/institutes/grid.51462.34
47 schema:startDate 2007-04-01T00:00:00Z
48 schema:subjectOf sg:pub.10.1186/2051-1426-1-20
49 schema:url https://clinicaltrials.gov/show/NCT00471133
50 sgo:license sg:explorer/license/
51 sgo:sdDataset clinical_trials
52 rdf:type schema:MedicalStudy
53 N2857001668f64ca9937363f3ea64b5fd schema:name Springer Nature - SN SciGraph project
54 rdf:type schema:Organization
55 anzsrc-for:3103 schema:inDefinedTermSet anzsrc-for:
56 rdf:type schema:DefinedTerm
57 sg:pub.10.1186/2051-1426-1-20 schema:sameAs https://app.dimensions.ai/details/publication/pub.1035943441
58 https://doi.org/10.1186/2051-1426-1-20
59 rdf:type schema:CreativeWork
60 https://www.grid.ac/institutes/grid.282549.0 schema:Organization
61 https://www.grid.ac/institutes/grid.51462.34 schema:Organization
 




Preview window. Press ESC to close (or click here)


...